Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0961203316680894 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Emerging B-Cell Therapies in Systemic Lupus Erythematosus.
Ther Clin Risk Manag
January 2021
Division of Pediatric Rheumatology, Steven and Alexandra Cohen Children Medical Center, New Hyde Park, NY, USA.
Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease of unknown etiology, whose hallmark is the production of autoantibodies. B cells are promising targets for novel SLE therapies. In 2011, belimumab (Benlysta), a fully humanized monoclonal antibody inhibiting B-cell activation and proliferation, was the first medication in 50 years to be approved by the US Food and Drug Administration to treat adult SLE.
View Article and Find Full Text PDFManagement of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab.
Drug Des Devel Ther
June 2021
Division of Pediatric Rheumatology, Steven and Alexandra Cohen Children's Medical Center of New York, Lake Success, NY, USA.
Belimumab (Benlysta) is a fully humanized monoclonal antibody that inhibits B lymphocyte stimulator (BLyS, also known as B cell-activating factor of the tumor necrosis factor family) and was approved by the US Food and Drug Administration (FDA) and the European Medicines Evaluation Agency for the treatment of autoantibody-positive systemic lupus erythematosus (SLE) in adults with moderate disease activity. Belimumab was recently FDA approved for use in children with SLE between 5 and 17 years of age. This review discusses the key findings of the belimumab phase III trials in adult SLE (via intravenous and subcutaneous administrations), phase II trial in pediatric SLE (intravenous administration), and post hoc analyses.
View Article and Find Full Text PDFPrevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus.
Lupus Sci Med
June 2020
Rheumatology, Columbia University Medical Center, New York, New York, USA.
Objective: To define the risk of progressive multifocal leukoencephalopathy (PML) in SLE.
Methods: This is a retrospective observational study to evaluate PML cases in patients with SLE admitted to two large academic hospitals. Using electronic medical record (EMR) data, International Classification of Diseases (ICD) codes identified PML cases among patients with SLE, rheumatoid arthritis (RA) (controls), had renal transplant and with HIV.
Validation of the 2019 European League Against Rheumatism/American College of Rheumatology Criteria Compared to the 1997 American College of Rheumatology Criteria and the 2012 Systemic Lupus International Collaborating Clinics Criteria in Pediatric Systemic Lupus Erythematosus.
Arthritis Care Res (Hoboken)
November 2020
Steven and Alexandra Cohen Children's Medical Center of New York, Lake Success, New York, and Hofstra Northwell School of Medicine, Hempstead, New York, United States.
Objective: Different classification criteria for systemic lupus erythematosus (SLE) have been proposed for many years. The most widely used and accepted criteria has been the 1997 American College of Rheumatology (ACR) criteria. In 2012, the Systemic Lupus International Collaborating Clinics (SLICC) criteria were published in an attempt to improve the clinical relevance of SLE criteria.
View Article and Find Full Text PDFEffectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies.
Clin Rev Allergy Immunol
April 2018
Division of Rheumatology, University of Padova, Via Giustiniani, 2, 35128, Padova, Italy.
To date, belimumab is the only biological drug approved for the treatment of patients with active refractory SLE. We compared and critically analyzed the results of 11 observational clinical-practice-based studies, conducted in SLE referral centers. Despite the differences in endpoints and follow-up duration, all studies remarked that belimumab provides additional benefits when used as an add-on to existing treatment, allowing a higher rate of patients to reach remission and to taper or discontinue corticosteroids.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!